Роль блокады ангиогенеза у пациентов с диабетической ретинопатией

    

    1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2: 17. doi: 10.1186/s40662-015-0026-2

    2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13): 1227–1239. doi: 10.1056/NEJMra1005073

    3. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003; 22(1): 1–29. doi: 10.1016/s1350-9462(02)00043-5

    4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000; 6(4): 389–395. doi: 10.1038/74651

    5. Файзрахманов Р.Р., Воропаев В.Ю., Суханова А.В., Шаталова Е.О. Анти-ангиогенная терапия неоваскулярной возрастной макулярной дегенерации. Вестник офтальмологии. 2021;137(1): 83–93. [Fayzrakhmanov RR, Voropaev VYu, Sukhanova AV, Shatalova EO. Antiangiogenic therapy of neovascular age-related macular degeneration. The Russian Annals of Ophthalmology. 2021;137(1): 83–93. (In Russ.)] doi: 10.17116/oftalma202113701183

    6. Файзрахманов Р.Р. Анти-VEGF терапия неоваскулярной возрастной маку-лярной дегенерации: от рандомизированных исследований к реальной клини-ческой практике. Российский офтальмологический журнал. 2019;12(2): 97–105. [Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Russian Ophthalmological Journal. 2019;12(2): 97–105. (In Russ.)] doi: 10.21516/2072-0076-2019-12-2-97-105

    7. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39(5): 469–778. doi: 10.5483/bmbrep.2006.39.5.469

    8. Ishida S, Usui T, Yamashiro K et al. VEGF164 Is Proinflammatory in the Diabetic Retina. Invest Ophthalmol Vis Sci. 2003;44(5): 2155–2162. doi: 10.1167/iovs.02-0807

    9. Lim JI, Spee C, Hinton DR. A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina. 2010;30(9): 1472– 1478. doi: 10.1097/IAE.0b013e3181d6df09

    10. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol. 2007;91(6): 822–886. doi: 10.1136/bjo.2006.109876

    11. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2009;148(6): 883–889. doi: 10.1016/j.ajo.2009.07.007

    12. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10): 1695.e1–15. doi: 10.1016/j.ophtha.2006.05.064

    13. Brucker AJ, Qin H, Antoszyk AN, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009; 127(2): 132-40. https://doi.org/10.1001/archophthalmol.2008.565

    14. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating shortterm effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6): 1009–1027. doi: 10.1097/IAE.0b013e318217d739

    15. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20): 2137–2146. doi: 10.1001/jama.2015.15217

    16. Bressler SB, Beaulieu WT, Glassman AR., et al. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology 2017; 124(4): 431-439. https://doi.org/10.1016/j.ophtha.2016.12.005

    17. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol. 2018;136: 1138–48. https://doi.org/10.1001/jamaophthalmol.2018.3255

    18. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, noninferiority trial. Lancet Lond Engl. 2017;389(10085): 2193–2203. doi: 10.1016/S0140-6736(17)31193-5

    19. Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab for proliferative diabetic retinopathy: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up. Retina 2017; 37(2): 334–343. doi: 10.1097/IAE.0000000000001181

    20. Lang GE, Stahl A, Voegeler J, et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy – the PRIDE study. Acta Ophthalmol. doi: 10.1111/aos.14312 (Dec 6 2019)

    21. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2): 213–216. doi: 10.1136/bjo.2007.127142

    22. Figueira J, Fletcher E, Massin P, et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology. 2018; 125(5): 691–700. doi: 10.1016/j.ophtha.2017.12.008

    23. Chatziralli I, Dimitriou E, Theodossiadis G, et al. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study. Acta Diabetol. 2020;57(10): 1219–1225. doi: 10.1007/s00592-020-01548-y

    24. Abdhish RB, Karisse T, Roy WB, et al. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3): 283–293. doi: 10.1001/jamaophthalmol.2013.2015

    25. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015;2015(8): CD008214. doi: 10.1002/14651858.CD008214.pub3

    26. Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol. 2018; 102(8): 1077– 1085. doi: 10.1136/bjophthalmol-2017-311344

    27. Wang DY, Zhao XY, Zhang WF, et al. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. Sci Rep. 2020;10(1): 18880. doi: 10.1038/s41598-020-75896-8

    28. Vidinova CN, Gouguchkova PT, Dimitrov T, et al. Comparative clinical and ultrastructural analysis of the results from ranibizumab and aflibercept in patients with PDR. Klin Monbl Augenheilkd. 2020;237(1): 79–84. (In Germ.) doi: 10.1055/a-0767-6951

    29. Коновалова К.И., Шишкин М.М., Файзрахманов Р.Р. Эффективность многоэтапного хирургического лечения пролиферативной диабетической ретинопа-тии, осложненной начальной катарактой. Вестник офтальмологии. 2020;136(6): 171–176. [Konovalova KI, Shishkin MM, Fayzrakhmanov RR. Effectiveness of multistage surgical treatment of advanced proliferative diabetic retinopathy complicated with primary cataract. The Russian Annals of Ophthalmology. 2020;136(6): 171–176. (In Russ.)] doi: 10.17116/oftalma2020136062171